TENX

Tenax TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$18.00

+64.4% vs current

Most likely

Base case

45%

Probability

Target price

$12.00

+9.6% vs current

B-

Bear case

30%

Probability

Target price

$7.00

-36.1% vs current

AI sentiment snapshot

Latest data as of 2026-04-17

AI commentary

Sentiment is balanced but cautious: the company has tangible clinical execution milestones, yet the setup is still dominated by one pivotal readout and by medium-term capital planning. With low coverage, loose peer support, and a negative deterministic prior, this looks more like a monitoring biotech catalyst story than a high-conviction long today.

RankAlpha Sentiment Codex - 2026-04-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30eventPhase 3 LEVEL topline data expected in Q3 2026High impact

Management said Tenax reached the randomization target of 230 patients in the LEVEL study, closed screening, and expects to share initial/topline results in the third quarter of 2026; this is the clearest near-term value inflection for the stock [#8-K-2026-03-10].

2027-06-30catalystFinancing or partnering decision as Phase 3 burn continuesHigh impact

The March 2026 update reported $97.6 million of cash at December 31, 2025 and said cash is expected to fund the company through 2027, but 2025 net loss was $52.6 million and R&D spend rose sharply as LEVEL and LEVEL-2 advanced; that leaves a meaningful risk that investors will focus on dilution or partnership timing before commercialization visibility improves [#10-K-2026-03-10][#8-K-2026-03-10].

2027-12-31catalystLEVEL-2 execution and enrollment progress into end-2027High impact

Tenax said it initiated the global Phase 3 LEVEL-2 trial, opened a long-term OLE study, and continues to expect LEVEL-2 enrollment completion by the end of 2027; steady site activation and enrollment updates would support the broader registrational thesis, while slippage would hurt confidence [#8-K-2026-03-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-17 • Updated nightlySource: Internal modelMethodology